Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Comparison of Combination Therapy With Tamsulosin and Dutasteride or Finasteride in Patients With Benign Prostatic Hyperplasia: A Randomized Clinical Trial Publisher



Basiri A1 ; Zare R1 ; Zahir M1 ; Kashi AH1 ; Zobeiry M2 ; Borumandnia N1 ; Abedi AR3 ; Golshan S1
Authors

Source: African Journal of Urology Published:2024


Abstract

Background: Based on our observations at the largest outpatient urology clinic in Iran, patients for whom finasteride is prescribed as a secondary drug to tamsulosin tend to experience earlier and more severe sexual side effects without any difference in the amelioration of symptoms. This study aimed to compare the time lag, efficacy, and side effects of combination therapy with varying doses of dutasteride or finasteride added to tamsulosin for benign prostatic hyperplasia (BPH) treatment. Methods: In this study 165 were randomized into 5 groups (each N = 33); receiving tamsulosin 0.4mg plus either of A: finasteride 3mg, B: placebo, C: dutasteride 0.25mg, D: finasteride 5mg or E: dutasteride 0.5mg. During the 6-month period of the study, International Prostate Symptom Score (IPSS), post-void residual urine (PVR), International Index of Erectile Function (IIEF-5), prostate volume (PV), prostate specific antigen (PSA) and maximum urinary flow rate (Qmax) were evaluated at baseline and at the 1st, 3rd and 6th month. The differences between each time point and baseline were then compared between groups. Results: At 3-month follow-up, group E exhibited a higher decrease in PSA but a greater increase in Qmax compared to group A (p = 0.047 and 0.006, respectively). Group C showed higher Qmax increase compared to group A at 3 and 6 months (p = 0.003 and 0.014) and concurrently a more pronounced PV decrease at 1 and 3 months (p = 0.047 and 0.003, respectively). Group D had a significantly more decrease in their IIEF-5 compared to group A at one-month visit (p = 0.006). Conclusions: In summary, at the sixth-month follow-up, dutasteride demonstrated superiority over finasteride solely in enhancing Qmax. Therefore, dutasteride may be marginally more beneficial as a secondary component of combination therapy in BPH. Trial registration IRCT, IRCT20120516009772N2. Registered 18 January 2021 Retrospectively registered, https://irct.behdasht.gov.ir/search/result?query=IRCT20120516009772N2. © The Author(s) 2024.
Related Docs
View other Related Docs
1. The Effect of Melatonin on Improving the Benign Prostatic Hyperplasia Urinary Symptoms, a Randomized Clinical Trial, Urology Journal (2022)
2. Sildenafil Vs. Tadalafil for the Treatment of Benign Prostatic Hyperplasia: A Single-Arm Self-Controlled Clinical Trial, Urology Journal (2023)
3. Evaluation of Efficacy of Cholecalciferol and Silymarin in Improving Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Double-Blind, Randomized, Controlled Trial, Urologia Journal (2024)
Experts (# of related papers)
View all Related Experts
Mohammad Reza Nowroozi (3)
Mohsen Ayati Efin (3)
Other Related Docs
4. Outcomes of Prostatic Artery Embolization for Treating Benign Prostatic Hyperplasia Symptoms: A Prospective Single-Center Study, Health Science Reports (2025)
5. A Two-Week, Double-Blind, Placebo-Controlled Trial of Viola Odorata, Echium Amoenum and Physalis Alkekengi Mixture in Symptomatic Benign Prostate Hyperplasia (Bph) Men, Pharmaceutical Biology (2017)
6. Lower Urinary Tract Symptoms in Hospitalized Patients With Covid-19, Journal of Iranian Medical Council (2022)
7. Clinical Value of Intravesical Prostatic Protrusion in the Evaluation and Management of Prostatic and Other Lower Urinary Tract Diseases, Asian Journal of Urology (2017)
8. Degarelix for the Treatment of Advanced Prostate Cancer Compared With Gnrh-Agonists: A Systematic Review and Meta-Analysis, Medical Journal of the Islamic Republic of Iran (2016)
9. Prominent Complaint: A Guide to Medical Therapy of Overactive Bladder Syndrome in Older Women, Acta Medica Iranica (2015)
10. Comparison of the Efficacy of Two Brands of Triptorelin (Microrelin and Diphereline) in Reducing Prostate-Specific Antigen and Serum Testosterone in Prostate Cancer: A Double-Blinded Randomized Clinical Trial, Nephro-Urology Monthly (2015)
11. Comparison of Tamsulosin and Tadalafil Effects in Luts Treatment Considering Patients' Atherosclerosis Risk Level, Annals of Medicine and Surgery (2022)
12. A Two-Week, Double-Blind, Placebo-Controlled Trial of Viola Odorata, Echium Amoenum and Physalis Alkekengi Mixture in Symptomatic Benign Prostate Hyperplasia (Bph) Men, Pharmaceutical Biology (2017)
13. Prediction of Medical Therapy Response of Benign Prostate Hyperplasia Patient’S According to Bladder Wall Thickness, Translational Research in Urology (2024)
14. Considering the Prominent Complaint As a Guide in Medical Therapy for Overactive Bladder Syndrome in Women Over 45 Years, Journal of Obstetrics and Gynaecology Research (2015)